MiniMed Group (MMED) Competitors

$10.80 -0.28 (-2.53%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$10.92 +0.12 (+1.11%)

As of 05/15/2026 05:32 PM Eastern

MMED vs. SNN, SOLV, PEN, GKOS, and BLCO

Should you buy MiniMed Group stock or one of its competitors? MarketBeat compares MiniMed Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiniMed Group include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Glaukos (GKOS), and Bausch + Lomb (BLCO). These companies are all part of the "medical equipment" industry.

How does MiniMed Group compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
MiniMed Group	N/A	N/A	N/A

In the previous week, MiniMed Group had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 4 mentions for MiniMed Group and 0 mentions for Smith & Nephew SNATS. MiniMed Group's average media sentiment score of 1.37 beat Smith & Nephew SNATS's score of 0.34 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Smith & Nephew SNATS	Neutral
MiniMed Group	Positive

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 19.7% of MiniMed Group shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Comparatively, 2.2% of MiniMed Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Smith & Nephew SNATS has higher revenue and earnings than MiniMed Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.05	$625M	N/A	N/A
MiniMed Group	$2.99B	1.01	N/A	N/A	N/A

Smith & Nephew SNATS presently has a consensus price target of $30.93, suggesting a potential upside of 4.64%. MiniMed Group has a consensus price target of $22.25, suggesting a potential upside of 106.02%. Given MiniMed Group's stronger consensus rating and higher possible upside, analysts plainly believe MiniMed Group is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40
MiniMed Group	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

MiniMed Group beats Smith & Nephew SNATS on 6 of the 9 factors compared between the two stocks.

How does MiniMed Group compare to Solventum?

MiniMed Group (NASDAQ:MMED) and Solventum (NYSE:SOLV) are both medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Solventum has higher revenue and earnings than MiniMed Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.01	N/A	N/A	N/A
Solventum	$8.33B	1.54	$1.56B	$8.16	9.10

19.7% of MiniMed Group shares are held by institutional investors. 2.2% of MiniMed Group shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MiniMed Group presently has a consensus price target of $22.25, suggesting a potential upside of 106.02%. Solventum has a consensus price target of $84.25, suggesting a potential upside of 13.46%. Given MiniMed Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe MiniMed Group is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Solventum had 6 more articles in the media than MiniMed Group. MarketBeat recorded 10 mentions for Solventum and 4 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.37 beat Solventum's score of 0.37 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solventum has a net margin of 17.33% compared to MiniMed Group's net margin of 0.00%. Solventum's return on equity of 23.51% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Solventum	17.33%	23.51%	7.63%

Summary

MiniMed Group beats Solventum on 7 of the 13 factors compared between the two stocks.

How does MiniMed Group compare to Penumbra?

MiniMed Group (NASDAQ:MMED) and Penumbra (NYSE:PEN) are both medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, MiniMed Group and MiniMed Group both had 4 articles in the media. MiniMed Group's average media sentiment score of 1.37 beat Penumbra's score of 0.50 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Penumbra has a net margin of 11.76% compared to MiniMed Group's net margin of 0.00%. Penumbra's return on equity of 10.87% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Penumbra	11.76%	10.87%	8.45%

Penumbra has lower revenue, but higher earnings than MiniMed Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.01	N/A	N/A	N/A
Penumbra	$1.45B	8.72	$177.69M	$4.34	74.25

19.7% of MiniMed Group shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 2.2% of MiniMed Group shares are held by company insiders. Comparatively, 2.9% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MiniMed Group presently has a consensus price target of $22.25, suggesting a potential upside of 106.02%. Penumbra has a consensus price target of $361.33, suggesting a potential upside of 12.13%. Given MiniMed Group's stronger consensus rating and higher probable upside, analysts clearly believe MiniMed Group is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Summary

MiniMed Group and Penumbra tied by winning 6 of the 12 factors compared between the two stocks.

How does MiniMed Group compare to Glaukos?

MiniMed Group (NASDAQ:MMED) and Glaukos (NYSE:GKOS) are both mid-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, MiniMed Group had 1 more articles in the media than Glaukos. MarketBeat recorded 4 mentions for MiniMed Group and 3 mentions for Glaukos. MiniMed Group's average media sentiment score of 1.37 beat Glaukos' score of 0.29 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiniMed Group presently has a consensus price target of $22.25, suggesting a potential upside of 106.02%. Glaukos has a consensus price target of $144.42, suggesting a potential upside of 0.62%. Given MiniMed Group's stronger consensus rating and higher probable upside, analysts clearly believe MiniMed Group is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

MiniMed Group has higher revenue and earnings than Glaukos.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.01	N/A	N/A	N/A
Glaukos	$551.35M	15.29	-$187.69M	-$3.28	N/A

MiniMed Group has a net margin of 0.00% compared to Glaukos' net margin of -34.34%. MiniMed Group's return on equity of 0.00% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Glaukos	-34.34%	-6.92%	-5.25%

19.7% of MiniMed Group shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 2.2% of MiniMed Group shares are held by company insiders. Comparatively, 5.8% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

MiniMed Group beats Glaukos on 8 of the 11 factors compared between the two stocks.

How does MiniMed Group compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and MiniMed Group (NASDAQ:MMED) are both mid-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Bausch + Lomb had 1 more articles in the media than MiniMed Group. MarketBeat recorded 5 mentions for Bausch + Lomb and 4 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.37 beat Bausch + Lomb's score of 0.13 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiniMed Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch + Lomb currently has a consensus price target of $18.08, suggesting a potential upside of 12.41%. MiniMed Group has a consensus price target of $22.25, suggesting a potential upside of 106.02%. Given MiniMed Group's stronger consensus rating and higher probable upside, analysts clearly believe MiniMed Group is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
MiniMed Group	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93

MiniMed Group has lower revenue, but higher earnings than Bausch + Lomb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.12	-$360M	-$0.62	N/A
MiniMed Group	$2.99B	1.01	N/A	N/A	N/A

MiniMed Group has a net margin of 0.00% compared to Bausch + Lomb's net margin of -4.21%. Bausch + Lomb's return on equity of 3.60% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
MiniMed Group	N/A	N/A	N/A

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 19.7% of MiniMed Group shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by insiders. Comparatively, 2.2% of MiniMed Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

MiniMed Group beats Bausch + Lomb on 8 of the 13 factors compared between the two stocks.

Get MiniMed Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MMED vs. The Competition

Export

Metric	MiniMed Group	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.03B	$3.36B	$4.74B	$12.48B
Dividend Yield	N/A	N/A	5.92%	5.25%
P/E Ratio	N/A	3.23	22.92	25.24
Price / Sales	1.01	29.71	121.17	82.47
Price / Cash	N/A	4.29	50.14	56.04
Price / Book	N/A	3.66	38.26	6.90
Net Income	N/A	-$76.79M	$113.55M	$334.66M
7 Day Performance	-6.66%	2.75%	2.46%	0.13%
1 Month Performance	-22.97%	2.15%	4.54%	1.12%
1 Year Performance	N/A	93.35%	16.80%	30.62%

MiniMed Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MMED MiniMed Group	4.1108 of 5 stars	$10.80 -2.5%	$22.25 +106.0%	N/A	$3.03B	$2.99B	N/A	8,000	Positive News Analyst Forecast
SNN Smith & Nephew SNATS	2.274 of 5 stars	$29.90 -0.5%	$34.75 +16.2%	+2.9%	$12.79B	$6.16B	N/A	16,988
SOLV Solventum	3.0936 of 5 stars	$73.30 +2.3%	$85.91 +17.2%	+1.8%	$12.71B	$8.33B	8.98	20,000	Analyst Downgrade
PEN Penumbra	3.2638 of 5 stars	$322.15 -0.8%	$361.33 +12.2%	+16.8%	$12.67B	$1.40B	74.23	4,700
GKOS Glaukos	2.2478 of 5 stars	$133.16 -0.7%	$144.42 +8.5%	+56.6%	$7.84B	$507.44M	N/A	1,094	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MMED) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiniMed Group (MMED) Competitors

MMED vs. SNN, SOLV, PEN, GKOS, and BLCO

How does MiniMed Group compare to Smith & Nephew SNATS?

Summary

How does MiniMed Group compare to Solventum?

Summary

How does MiniMed Group compare to Penumbra?

Summary

How does MiniMed Group compare to Glaukos?

Summary

How does MiniMed Group compare to Bausch + Lomb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MMED vs. The Competition

MiniMed Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiniMed Group (MMED) Competitors

MMED vs. SNN, SOLV, PEN, GKOS, and BLCO

How does MiniMed Group compare to Smith & Nephew SNATS?

Is SNN or MMED more profitable?

Does the media prefer SNN or MMED?

Do institutionals and insiders have more ownership in SNN or MMED?

Which has better valuation & earnings, SNN or MMED?

Do analysts prefer SNN or MMED?

Summary

How does MiniMed Group compare to Solventum?

Which has better earnings and valuation, MMED or SOLV?

Do institutionals & insiders have more ownership in MMED or SOLV?

Do analysts rate MMED or SOLV?

Does the media favor MMED or SOLV?

Is MMED or SOLV more profitable?

Summary

How does MiniMed Group compare to Penumbra?

Does the media favor MMED or PEN?

Is MMED or PEN more profitable?

Which has stronger earnings & valuation, MMED or PEN?

Do insiders and institutionals have more ownership in MMED or PEN?

Do analysts rate MMED or PEN?

Summary

How does MiniMed Group compare to Glaukos?

Does the media favor MMED or GKOS?

Do analysts rate MMED or GKOS?

Which has stronger earnings & valuation, MMED or GKOS?

Is MMED or GKOS more profitable?

Do insiders and institutionals have more ownership in MMED or GKOS?

Summary

How does MiniMed Group compare to Bausch + Lomb?

Does the media prefer BLCO or MMED?

Do analysts prefer BLCO or MMED?

Which has preferable valuation & earnings, BLCO or MMED?

Is BLCO or MMED more profitable?

Do institutionals and insiders hold more shares of BLCO or MMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MMED vs. The Competition

MiniMed Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools